CBD Health

Imagine waking up in the middle of the night and feeling pain go into your hands and feet. It’s so bad it feels like someone is stabbing you! The throbbing and penetrating feeling brings you to tears. It’s bad enough that the intensity is so painful, but imagine that this happens every night of your life now. This would send the strongest person into the worst of depression.

So what are you doing? Turn on your lights and grab the bottle of pain medication. Makes sense right? You try to open the bottle and only find that it feels like it weighs a thousand pounds !!! You struggle in frustration that the pain is preventing you from opening up something so small that should be easy. Finally, after minutes that feel like an eternity, the bottle is finally open. You grab some pills and swallow them like someone who hasn’t eaten in a month. Now sit and wait for the pain to stop! After an hour or so, it finally looks better and you are relieved that you can now try to get back to sleep. Morning comes and you feel tired and frustrated. Yes you could fall asleep but the quality was terrible. Your body feels like it has just done 10 laps with Mike Tyson. Worst of all, your stomach is knotted from the pain relievers. You feel miserable and hopeless !!

This is the reality for anyone with neuropathy or nerve pain, and they experience it on a daily basis. It is sad to hear and see that such a technologically advanced world still relies on pain relievers with unpleasant side effects. It would be great if they actually worked, but we hear from our patients that they are not even sure if anything is happening at all. So you are taking a drug that is not working and has side effects. Does that sound like a good offer now? We can fly a robot to Mars, but we can’t do enough research to find a better solution for people coping with neuropathy and nerve pain.

So the question is, why didn’t they? Is there anything better than antidepressants, anti-seizures, or opioids for neuropathic nerve pain?

How much money do you think is being made from neuropathic pain relievers? 1 million, 1 billion, what do you mean? The answer is a whopping $ 5 billion a year !!

So if drug companies are making $ 5 billion plus a year on these drugs, why should they invest in research or better alternatives for patients? From a business point of view, it doesn’t make sense. Neuropathy is not a condition that goes away; it is increasing at an alarming rate. There are so many causes of diabetes, chemotherapy, surgery, blood pressure and cholesterol medication, inflammation-related causes, and hundreds of other causes. If you look at the scope and size of these numbers, the market will only go up.

How does the pharmaceutical business balance the business of utility versus money? That is the question. Will Big Pharma continue to give people drugs that in many cases will eventually become ineffective? Is it okay to give patients drugs that cause other health problems? Unfortunately, the answer for these companies is yes. For them it’s about the money. They know their drugs have side effects, but it’s a small price to pay for them.

So how do you break out of this form? How do you take yourself out of the matrix and become a neo? The answer is CBD.

My specialty is neuropathy. CBD topicals have been a miracle for my patients. It made it possible for them to live again. They could replace their pain medication with cbd. You have reported so many great things about using the topical cream. Do I think CBD in other forms may be effective for neuropathic patients? The answer is yes. Personally, I did not take this route because our patient base is usually at high risk and takes a lot of medication. So we have to be very careful when introducing something new to our patients.

Can you imagine waking up in pain every day with no relief? We will never be able to understand the life of someone living in pain 24/7. So we have to do more. We have before us something so powerful with proven benefits. It has been shown to be superior to some of the pain remedies. I believe that CBD was placed on this earth for a reason. Regardless of your religious beliefs, I believe that CBD has a bigger purpose. The world is very sick and we are starting to see it more and more. It seems like life now is about instant gratification, not lifelong happiness. Happiness means being healthy and doing the things that you want to do on your terms. If we wait for the drug companies to research and find out that CBD is the holy grail, good luck. Knowing your story, you will find a way to mess it up.

So it is up to us as people, doctors and entrepreneurs to push the boundaries on all fronts. Our message must be clear and simple. The words that people hear and see must be based on common sense. CBD has very powerful anti-inflammatory and immunosuppressive properties. Inflammation is a complicated process that involves many signaling pathways. The body uses signaling molecules called eicosanoids to trigger the inflammatory response.

One of the ways CBD can reduce inflammation is by blocking an eicosanoid enzyme called COX2. NSAID drugs such as Advil and Aspirin also target COX2 in their mode of action. Wouldn’t it be great to get to the point where we all know 2 ibuprofen is that much CBD? That you could take it and not have the side effects. It is amazing that something that came from this earth can save your life. Is that a crazy thought or what ??

The science of CBD is clear. It creates balance in the body. Any type of pain is always a dysfunction of a chemical, structural, or neurological system. This is the methodology of how health problems typically arise. What does cbd do in general? It creates balance in the body. From a cellular point of view, when equilibrium occurs, repair also takes place. Now let’s take this concept to the next level. What if you can add other things to CBD? Adding amino acids or nutritional supplements to create better harmony in the body. Give your body everything it needs to function. What would happen then? Specific proteins are produced, nerve growth factors multiply, and cell repair begins. It is as if the seas parted before Moses. Life happens again. Life begins to become comfortable again for people. I’ve seen it over and over in my practice. Life without pain medication is possible. It just takes more people who think differently, talk about it, research, test, and push the envelope to get it into mainstream conversation. We have to be better than big pharmaceutical companies. Money is always part of the equation, but it doesn’t mean people are getting an inferior solution.

In the famous words of Jerry Maguire, “You complete me”. Let’s do more and be more with CBD.

As the cannabis and CBD industries continue their rise to the forefront of the American market, new regulations governing the packaging of products are quickly becoming a cause for concern.

Data compiled by MjBizDaily showed that the economic impact of marijuana is up 30% from 2020 and is expected to reach $ 92 billion this year. Sales of $ 160 billion are forecast for 2025.

With the industry’s wide range of products now exploding on shelves, established companies and business models are starting to feel the heat. Concerns about clear labeling, parental controls, and sustainability are mounting as major confectionery manufacturers complain about packaging confusion.

Lisa Buffo, Founder and CEO of the Cannabis Marketing Association, said, “Packaging is a critical touch point for the cannabis user.”

“This is the first step they take when physically interacting with the product,” she said. “What information is on the packaging? Is it something that the consumer can read and understand? Will this information change the way they use the product and improve their understanding of what is in it? “

A recent report published by Grand View Research, Inc. showed that increasing legalization and demand for medical and recreational cannabis around the world is projected to reach the legal marijuana market size of an estimated $ 73.6 billion by 2027.

More than 60% of cannabis users surveyed by the Brightfield Group said they prefer labels describing a product’s THC content and type of strain (indica, sativa, hybrid), while nearly 50% said they also list the Want ingredients.

Here are the current concerns about cannabis and CDB packaging.

Clear labeling / milligrams per dose

Unfortunately, the requirements for product labeling information vary significantly in each US state. While every state required delta-9 tetrahydrocannabinol content and manufacturer’s contact information, only 80% of states required the lot number, health risks, production tracking, a cannabis symbol, cannabidiol content, child disclaimer, and impairment disclaimer.

Patricia Miller, Editor-in-Chief of Cannabis and technology today, said: “Most cannabis products are subject to strict regulatory supervision, but without a certificate of analysis, consumers have no way of knowing what they are consuming and how much.”

In addition, “many of the test facilities have had to develop their own test methods and the result is lab-to-laboratory variability,” she said.

For CBD products, basic labeling requirements include a scannable barcode or QR code to make it easier to see the batch identification number, product name, batch date and size, Expiry date, total quantity produced, ingredients or certificate of analysis. Product requirements also include an FDA warning, no medical or health claims.

Keep out of reach of children

Since there are so many different standards for cannabis packaging, this is the New York Times reported that the big candy manufacturers are upset over similar THC goodies. According to the article, Wrigley’s and others protect not only their brands but your children as well.

In fact, Wm. Wrigley Jr. Co., owned by Mars Inc., filed lawsuits against five companies in May for selling cannabis-infused edibles that look like Skittles, Starburst, and Life Savers.

While incumbent product manufacturers have raised concerns about similar packaging, Miller said that some cannabis companies are not satisfied with the requirement for child-resistant packaging because alcohol brands are not packaged in child-resistant containers and there is the potential for fatal overdose.

“Parental controls are largely a by-product of the lingering stigma surrounding cannabis,” she continued. “But these regulations help people feel more comfortable having cannabis products at home, so they are ultimately good for the industry.”

According to the Child Mind Institute, not only are adults experimenting with CBD for anything that bothers them, but increasingly parents are turning to CBD to help their children focus, sleep, calm down, and more.

What does the box look like?

Nobody has to tell you that the usual packaged cannabis products are time sensitive. In addition, the brands also want space on the packaging to market their product.

In addition to light, UV rays, moisture, and gases that can potentially ruin the product inside, cannabinoid-infused beverages still struggle to create formulations that prevent the active ingredients from entering the package and becoming inert.

While the freshness and shelf life of cannabis products are always a concern, the brand’s ability to market the product is also hampered by the requirements of regulations and child-proof copies.

Buffo said because they have to use child-resistant packaging and affix labels with product information and health warnings, “it often leaves little to no room for branding, consumer education or design innovation.”

“Brands need to get creative to improve the customer experience and communication with their customers when packaging space is limited,” she continued. “In addition, the products are often behind the counter and are only handed over to the customer after they have been purchased, so that there is no need to touch or read when shopping.”

On the CBD side, cosmetic and personal care products have found incredible appeal with consumers in a relatively short period of time, which has led to a noticeable packaging development, so Beauty packaging.

To be green or not to be green

Similar to many other sectors in the world market, single-use plastic products have become a hurdle for packaging in the cannabis industry. Although their use became a popular alternative during the COVID-19 pandemic, single-use plastic bags are on the way out as sustainability concerns resurface.

Miller said the cannabis industry’s biggest problem is waste.

“While child safety and traceability regulations have created a monster from RFID tags to individual pre-roll tubes, single-use plastics are an environmental concern.”

Going forward, industry experts believe government and industry need to focus on what packaging is appropriate and necessary to improve the process for brands, customers and the environment.

From both cannabis and CBD packaging perspectives, companies should consider whether the materials are of natural origin, whether they are biodegradable, recyclable, and how much energy is required for recycling?

Are the materials also reusable or disposable designs, do they contain added harmful chemicals and is the company itself committed to sustainability?

Additionally, CBD and cannabis products wrapped in paper and made from cannabis-based materials will also improve sustainability.

About the author:

Mark McClure is Vice President of Operations at the flexible packaging company International Plastics in Greenville, SC

https://www.interplas.com/

Technical background

With technological advances and growing consumer interest in CBD / THC-infused beverages, Industrial Sonomechanics (ISM) has seen significant activity and business growth in its technology for making water-compatible CBD and THC formulations, as well as the manufacture of finished nanoemulsions products. ISM’s technology is a complete solution that includes high amplitude ultrasonic liquids on laboratory, laboratory and industrial scale Processors in connection with several All-In-One NanoStabilizers® Formulations.

With this solution, ISM’s customers are fully able to commercially manufacture translucent water-soluble nanoemulsions of cannabis extracts that can be easily infused into water and other beverages cannabinoids.

A typical nanoemulsion concentrate produced with ISM technology contains between 10 and 50 mg / ml cannabinoids, which are suspended in the form of nanoscale droplets with an average diameter of around 20-30 nm, which ensures permanent water tolerance, translucency and long-term stability . When about 0.2 – 1 ml (depending on the concentration and required dose) of nanoemulsion is infused in water (see pictures below), the translucency turns into complete transparency and results in a clear cannabinoid-infused water-based product.

ISM’s technology also enables the production of water-soluble CBD and THC powders and tablets as well as a wide range of water-compatible nanoemulsions of aromatic oils and many other hydrophobic bioactive ingredients.

Trends in bioactive ingredients

We look at the ingredients of cannabis beverages from two consumer-oriented perspectives. First, what is the desired cannabis beverage consumer experience? Is the consumer interested in the therapeutic benefits of just relaxing in the evening, both? Second, what is the vehicle for consumption and the desired look and taste of the product? With today’s nanotechnology, consumers can take advantage of infused bioactive ingredients like CBD and Delta-9 THC, and we are seeing a significant increase in the rating of Delta-8 THC properties.

Based on these perspectives, manufacturers can formulate CBD and / or THC products with the desired effects. As a result, consumers can determine what they want and expect from their product, so that companies, with the right equipment and formulations, produce high quality products that allow short exposure times with predictable and reproducible potency.

At the beginning of the CBD / THC infused beverage market curve, we saw many low quality emulsions with large droplet sizes (in the hundreds of nanometers) and the appearance of absorbing milk that were not readily available to the body. With the advancement of industry, made possible by high amplitude ultrasonic devices and better emulsifier formulations, translucent nanoemulsions with much smaller droplet sizes quickly began to replace milky emulsions. Translucent nanoemulsions are in great demand because their extremely small droplet sizes enable high bioavailability, short action times and predictable duration of action. They also have the advantage that they do not change the appearance of the drink, as they become transparent when diluted.

We are currently also seeing a rapidly growing demand for water-soluble CBD and THC powders that, when added to a beverage, reconstitute to their original nanoemulsified state (just like adding sugar to coffee). Powders also enable a wide range of applications and finished products – for example, they can be compressed into tablets that break down immediately in the mouth and dissolve in saliva, or they can be formulated as effervescent tablets that dissolve quickly in beverages.

Taste trends

While it’s not always obvious, cannabis extracts are bitter. It is important to remember that the taste of a substance cannot be felt if the substance is not dissolved in saliva. Refined CBD and THC extracts, distillates, and isolates may not appear bitter when tasted directly because they do not dissolve in water (or saliva). The formulation as a nanoemulsion makes it compatible with water and thereby increases its bioavailability, but also enables our taste buds to perceive its bitterness.

We see two different preference trends in terms of taste. Many consumers enjoy and are still looking for a “homegrown flavor” in which they can taste the terpenes and flavonoids of the original plant in the drink. This comes as a surprise to some, but others want to identify deeply with what they are consuming. Of course, there is a second preference where consumers want to try something that they really like, but not necessarily related to the flavors of the original plant. In other words, you want to mask the taste of the extract and / or cover it with other flavors. To this end, we constantly see requests for masking agents and water-soluble flavor additives. We have recently started offering such products.

Cannabis drinks can be a bit like alcoholic – an acquired taste. Some consumers like the natural taste of cannabis, similar to those who love a peaty scotch. Others find the taste unpleasant and would rather suit the hard seltzer drinkers of the world. The industry is learning that not every taste in the CBD / THC beverage space is monolithic. If there is a market for a particular flavor profile or flavor, the industry will adapt. Given the tools and product options, the branders, designers, and marketers will be there to meet this need.

Technological innovation trends

In our opinion, the most important technology trend in product development is particle size. Water-compatible nano-emulsified beverage products with a focus on small particle sizes are at the core of the future market introduction of THC / CBD products, as they enable consumers to trust their quality, effect and taste.

The trend is towards nanoemulsions with the smallest possible droplet sizes. This applies to liquid nanoemulsions as well as water-soluble powders and tablets, which reconstitute themselves in water (or saliva) to form nanoemulsions. Droplet size has a direct impact on all of the major benefits of nanoemulsion-based products, including translucency, bioavailability, and onset of action. In order to absorb oils and fats from our food, the digestive system usually first “reforms” them into mixed micelles – droplets with mean droplet diameters around 20 nanometers. This is what our small intestine can absorb most efficiently. It is therefore important to keep the droplet sizes in nanoemulsion-based products close to this value for maximum benefit.

ISMs Barbell horn® ultrasound technology-based processors and NanoStabilizer® formulations enable its customers to easily produce nanoemulsions with droplet sizes of only 20-30 nm CBD or THC absorbed into the bloodstream very quickly and completely. Our processors can output extremely high ultrasonic amplitudes and operate at any scale, allowing manufacturers to quickly move from a laboratory to a production environment to meet the growing (and ever-changing) consumer interest in infused beverages.

In the next two years, there is likely to be rapid advancement in the CBD and THC infused beverage market. Companies have to act quickly and with agility when they bring new products onto the market that are reliable and of consistent quality. Technology needs to be coupled with consumer education, which in turn is supported by research. Science-oriented institutions, technology companies and informed consumers will be great partners in advancing technology and innovation in the beverage industry.

About Industrial Sonomechanics, LLC.

Industrial Sonomechanics, LLC (ISM) is a research and development, equipment design, and process consulting firm specializing in high-intensity ultrasonic technology for fluid treatment. Our mission is to support companies in optimizing their ultrasound-based processes and implementing them in commercial production. Learn more about ISM at sonomechanics.com.

Cannabidiol (CBD) provides many therapeutic benefit, such as to reduce pain, anxiety, and inflammation. The trick is figuring out how much CBD to take in order to maximize the positive effects. Some people take CBD and do not notice anything. Others may find that CBD is causing the undesirable effects of drowsiness. [1]

We are individuals with unique body compositions. There is no such thing as “one size fits all” when it comes to dosing CBD. Fortunately, medical cannabis experts offer advice to help consumers find the right dose of CBD.

CBD doses vary with the individual

CBD dosage can be difficult to determine. Dr. Dustin Sulak explained that “We all have unique internal chemistry and the cannabinoid system is very complex, so very different dosages are best for different people.”

Doctors can set a specific starting amount based on the patient’s weight. Clinical studies typically measure doses based on the patient’s weight – for example, as milligrams (mg) of CBD per kilogram (kg) of body weight (one kilogram is roughly 2.2 pounds). In a review of over 1,000 clinical trials of CBD, effective doses for various ailments ranging from less than 1 mg / kg up to 50 mg / kg were reported. [2] That means a 150-pound person (clinically) can benefit from a daily dose of CBD under 70 mg; You can also benefit from a daily dose of 3,500 mg! [2]

Dr. Sulak notes that some patients respond well to very small doses of 3-5 mg; others may need 300-500 mg. High doses may be more suitable for people with severe medical conditions. Low doses have the advantage of affordability.

DR. Rachna Patel describes two patients of similar body shape and size who suffered from insomnia. To improve sleep, one needed 2.5 mg of CBD; the other needed 50 mg of CBD.

It’s easy to see why CBD dosage creates so much confusion.

How to find the right dose of CBD

Medical experts often resort to the saying “start low and go slow”.

The Arthritis Foundation^®recommends starting with “just a few milligrams of sublingual CBD twice a day”. If this protocol does not give results, the consumer can titrate up a few milligrams after a week. You continue this titration process until the desired results are achieved.

Dr. Neal Smoller offers a less rigorous, albeit similar, approach, advisory Consumers to start with a low dose, record their experience, and try another dose after 4 hours as needed.

Dr. Sulak helps patients find the right dose within four days. note that “ultra-low doses can be extremely effective, sometimes even more than the others” [high-dose] extreme.”

Finding out how much CBD is right for you requires trial and error. Some benefit from low doses while others require high doses. Medical cannabis experts almost always recommend starting low, going slowly, and titrating to success.

References

1- Huestis M, et al. Cannabidiol side effects and toxicity. Current neuropharmacology. 2019; 17: 974-989. 10.2174 / 1570159X17666190603171901

2- Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosage in clinical populations. Br J Clin Pharmacol. 2019; 85 (9): 1888-1900. doi: 10.1111 / bcp.14038

Picture: Erin Stein the end Pixabay

Before the hype train with mainstream icons like Kim Kardashian on board, CBD was long an obscure cannabinoid that only a handful of scientists believed in. In fact, its long and bumpy road stretches back to ancient times.

Many sources cite Sheng Neng, an ancient Chinese emperor, as the first known cannabis user. A document from the year 2737 BC. BC shows how he used cannabis-infused tea as a remedy for malaria, rheumatism and others.

In 1839, William O’Shaugnessy, an Irish medical researcher, conducted the first study that provided insight into the therapeutic potential of cannabis and sparked the interest of the scientific community.

During the last decade of the 19th century, Queen Victoria apparently relied on cannabis to relieve her menstrual cramps, according to the records of her private doctor.

Evidence of CBD’s rocky relationship with the law is the fact that it was discovered by Roger Adams in 1940 just 3 years after cannabis was illegalized in 1937. As a reference, THC was not isolated until 1964, largely attributed to Roger Adams’ discovery.

In 1946, the first CBD-specific study by Dr. Walter Loewe carried out on laboratory animals.

In the 1970s, things started looking for CBD legally.

In 1973, Oregon became the first state to legalize medical cannabis. In 1978, the medicinal potential of cannabis was officially recognized by the Controlled Substances Therapeutic Research Act.

This, of course, opened the door to studies in particular on cannabis and CBD.

In 1980, Dr. Mechoulam conducted a study that shed light on the anti-seizure properties of CBD. After several years and studies of CBD as a cure for epilepsy, we are entering the pivotal year 2018 when the FDA approved the first CBD drug, EPIDIOLEX, for the treatment of epilepsy. This victory cannot be celebrated without mentioning the famous case of Charlotte Figi, a young Colorado girl plagued by 300 epileptic seizures per week, reduced to 2-3 per month with CBD.

Now, CBD seems to have finally escaped the stigma of its parents’ illegal past. People from all walks of life and status are trumpeting its power, including many famous UFC fighters like Nate Diaz, which is clear evidence not only of the cannabinoid’s legitimacy and effectiveness, but also of its long overdue mainstream acceptance.

“Better late than never” was seldom more appropriate.

Cannabis licensing issues are set to become the next battlefield in the US as legalization becomes more likely, reports CBD-Intel

With the majority of anti-cannabis users appearing to have accepted the eventual inevitability of some form of legalization, attention now turns to attempts to influence the shape of a possible future regime.

Traditional adversary industries like pharmaceuticals and alcohol have recently changed at least part of their lobbying strategy.

They are now trying to create limited licensing models that would benefit them as better funded companies by either dominating the market itself or limiting its impact on their core business interests.

John Kaweske, CEO of Tweedleaf, a Colorado medical and adult pharmacy chain, told CBD-Intel that outside government officials remain a threat to continued cannabis use.

By lobbying to limit licenses and introduce stricter licensing systems, companies that previously opposed cannabis are trying to create the kind of highly regulated, constrained market conditions for gamblers under which they already thrive. That is, they either beat back the competition by creating the conditions for artificially high prices, or they create a market into which they can enter themselves with considerable financial and experiential advantages.

“The concern of Special Interests is that they try to gain oligopoly-like advantages,” said Kaweske. “States with a restricted licensing model are simply un-American and violate free market principles.

“If the government creates a system of limited licenses and only issues those licenses to a small group of people, how does the American dream come true?”

Aside from concerns about allowing more people – especially those most disadvantaged by the decades-long war on drugs – to enjoy a slice of the lucrative cannabis pie, restricted licensing also hurts consumers directly as it leads to higher prices.

“In limited license states, the cost of cannabis is literally double what our consumers here in Colorado pay for the same product,” added Kaweske. “The consumer pays the price because of this restrictive market.”

But some of the larger cannabis companies can also benefit from limited licensing. This has created a messy situation with sometimes weird bedfellows.

For example, the Michigan Cannabis Manufacturers Association (MCMA), which represents some of the largest cannabis companies in Michigan, is campaigning for stricter regulations on medical cannabis caregivers and possibly more restrictions on home growing.

In essence, the MCMA wants to get as many sales as possible through licensed pharmacies for the benefit of its members.

However, current regulations allow medical cannabis keepers to support up to five patients, which can include growing as well as sourcing supplies from outside the pharmacy system.

This could mean growing up to 12 cannabis plants or purchasing up to 2.5 oz of product for the five patients, which could be combined with personal growing allowances if the caregiver is themselves registered as a medical cannabis patient to grow up to 72 plants.

The Michigan Medical Marijuana Association (MMMA) estimates that there are more than 36,000 registered nurses who could potentially care for a significant portion of the state’s 267,000 medical cannabis patients, according to the MMMA, removing them from the state’s licensed medical cannabis market, which is estimated to be around Estimated $ 1 billion.

The motivation for the companies that make up the MCMA to work to limit potential routes out of the market is obvious. MCMA members say they are concerned about the impact unregulated, unchecked and untaxed medical cannabis could have on consumers and government programs that rely on money.

But there have been calls from cannabis activists to boycott brands associated with membership of the trade group, including Fluresh, Two Joints, Jolly Edibles, North, Short’s Brewing, Petra, Wana, Sherbinski’s, Kiva Confections, DNA Genetics, Clout King , Chief Solventless and Crown Jewels.

Rick Thompson, owner of Michigan Cannabis Business Development Group, called any changes “unnecessary” and referred to the story of MCMA’s executive director Steve Linder.

“You have to acknowledge that Linder has been a real problem for the cannabis industry for years,” Thompson told the local media. “The consistent message from him and the MCMA was to put all cannabis sales under regulation.

“They want more sales to go through their stores. They advocate fundamentally changing the way nurses work to the extent that most of us believe that the program will be fundamentally changed and inoperable. “

The MCMA move puts them on the same side as pharmaceutical organizations that previously urged Michigan lawmakers to restrict nurse activity.

Similar activity can be seen on the recreational cannabis side.

A major problem for companies in states that allow alcohol and cannabis use on the same site is getting cities and other local jurisdictions to rewrite land use policies so that cannabis is visible. There’s also a problem with rewriting the zone restrictions so cannabis businesses can open in more desirable locations, according to House Caviar, a Los Angeles-based event planning company.

This has traditionally been opposed by the alcohol industry, which fears lost sales of cannabis in co-licensed locations, Antoinette Vu, co-founder of House Caviar, told CBD-Intel.

But local jurisdictions often prioritize tackling homelessness and unemployment in changes in land use policies – two social problems often linked to the war on drugs through convictions and other means.

This makes it easy for lobbyists to push other issues with public support and keep cannabis-related changes on the agenda, Vu added.

Ironically, many cannabis companies dealing with social issues such as homelessness and unemployment due to drug convictions could re-lobby on the same side of issues as those seeking to restrict cannabis licensing.

And the same shared loyalties can be seen at the federal level. Members of Congress have proposed several bills related to the legalization of cannabis, including:

• the highly progressive Cannabis Administration and Opportunity Act, which would remove cannabis from the controlled substances list
• the Moderately Progressive Marijuana Opportunity Reinvestment and Expungement (MORE) Act, a more progressive edition than the version passed by the House of Representatives last year
• the Common Sense Cannabis Reform For Veterans, Small Business, and Medical Professionals Act, which would replace the reinvestment and opportunity elements of the MORE Act with legalizing interstate cannabis trade, medical cannabis research, and providing access for military veterans.

Again, issues of social justice and opportunity lead to shared loyalties, with some in the industry advocating any kind of incremental change to slowly bring about a new federal cannabis regime. Others take the position of Democratic Senator Cory Booker of New Jersey and are less opposed to action aimed at promoting broader legislation.

Some companies outside of the cannabis sector, such as Amazon, have publicly supported measures such as the MORE Act. Amazon declined to tell CBD-Intel whether it had backed its public support with money from lobbyists.

Similarly, Big Alcohol and Big Tobacco in particular are silent about their lobbying activities alongside general inclusive propaganda. However, there is a feeling that such companies would be at a disadvantage in terms of either dominance or the safeguarding of their core interests if the focus were on accessing and improving under-represented communities and limited businesses.

As a result, the general activity of traditional cannabis opponents remains worrying – not least because of their much larger war coffers. It has been estimated that cannabis lobbyists spent only $ 4 million on political advocacy last year, compared to the $ 60 million alcohol and tobacco groups contributed to all issues.

A survey of its members conducted by the national cannabis advocacy group NORML found that a majority of consumers do not support alcohol and tobacco companies that influence cannabis policy. A total of 77.6% said it was a problem, just under 47% said it was a big problem and the rest said it was only a problem “when companies advocate policies that address consumer issues There is a conflict ”.

“We have already seen the impact of these corporate interests,” said Erik Altieri, NORML’s Executive Director. “In some cases, many of these people have opposed consumer-friendly legalization regulations, such as the right for adults to grow marijuana in the privacy of their home.

“These business units have also pushed for statewide limits on the number of licensed cannabis producers and dealers to keep prices high and artificially limited – and keep the economic benefits of legalization largely out of the reach of the average American,” especially People of Color. “

What that means: NORML’s concerns are understandable. It is interesting to note that in terms of legalized territory and acceptance, cannabis is growing, it is also becoming more corporate.

Natty Suits and Flash Cars are rapidly replacing RVs and patchouli, potentially bringing the industry into greater conflict with itself – especially as parts of them realize they have more in common with the lobbying positions of former external opponents.

Vigorous prohibitionists are increasingly being sidelined. Even longtime traditional lobbyist opponents like Safe Approaches to Marijuana have changed course from advocating a ban to advocating restrictions while continuing to warn of potential dangers.

With increasing pressure to change at the federal level and in the remaining prohibition states, it will be interesting to see where the money is going and how issues such as licensing and land use develop.

What is clear for now is that there is unlikely to be a clear divide between those within the sector and those outside the sector.

–

CBD-Intel (www.CBD-Intel.com) provides impartial, independent and world-class market and regulatory research, law enforcement and quantitative data for the cannabidiol (CBD) sector.

We offer our clients the tools to navigate this fast-moving sector, adjust their business strategy, optimize resources and make informed decisions. In addition, we offer tailor-made research and advice support.

As people discover the benefits of the non-psychoactive cannabinoid cannabidiol (CBD), they wonder if it could benefit their animal companions as well. However, human and animal bodies process cannabinoids differently [3]. So what do we really know about the paw print of CBD in the cannabinoid world?

Important points

• If you give your dog a larger single dose of CBD, the effects won’t get any stronger [3].
• Dogs get more CBD from an oral dose than humans [3].
• Dogs and cats require different dosages of CBD [1].
• Traces of THC in CBD products can have negative effects on pets [4].
• Always speak to your veterinarian before giving CBD to your pet.

Research on CBD for dogs was published back in 1988 [3]. This study tested pure CBD given intravenously or orally to dogs. The researchers found that the effects of CBD in dogs were not dose-dependent. This means that if you give the dog more CBD, you won’t necessarily get more potency. They also found that oral bioavailability (the amount of active CBD in the body) was 13% to 19%, which is better absorption than humans.

People give CBD to dogs and cats for disorders related to anxiety, seizures, cancer, and pain [1]. A 2019 research paper explains that cats have a higher rate of oral absorption than dogs. Overall, CBD appears to be well tolerated by adult dogs, but less is known about CBD for cats. For this reason, it is extremely important to speak to your veterinarian before giving CBD products to your dog or cat. Only they can advise you on the correct dosage for your pet. Since CBD can have side effects and drug interactions, they can also tell you whether it is safe for your pet to take CBD.

Now that we’ve talked about CBD dosage for dogs and cats and how they absorb CBD, let’s consider whether CBD is actually beneficial for pets. In a 2018 study, dogs with osteoarthritis were given CBD oil and their pain level was assessed after four weeks [2]. Overall, the dog’s pain level appeared to be decreasing and its activity level improved. The dogs were also allowed to receive NSAIDs, fish oil, and / or glucosamine / chondroitin sulfate. This study is far from final, but it does give us the insight that when combined with standard veterinary treatment, CBD can improve dog health and reduce pain associated with osteoarthritis.

Finally, choosing the right CBD product for your pet is important. Your veterinarian is the most qualified person to make a recommendation. Much care needs to be taken as even traces of the psychoactive tetrahydrocannabinol (THC) can cause side effects to your dog. While most of the CBD side effects are mild, people can also tolerate THC better. A 2020 study observed that dogs given CBD containing traces of THC experienced side effects such as lethargy, hypothermia, and ataxia (loss of complete control over body movements). [4]. So watch out for such side effects, opt for CBD isolate for pets and always speak to your veterinarian!

References

1- Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment of the use of high-CBD hemp nutraceutical in healthy dogs and cats. Animals. 2019; 9 (10): 832. doi: 10.3390 / ani9100832

2- Gamble LJ, Boesch JM, Frye CW et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Limits in Veterinary Science. 2018; 5. doi: 10.3389 / fvets.2018.00165 Retrieved August 12, 2021. https://internal-journal.frontiersin.org/articles/10.3389/fvets.2018.00165/full#h3

3- Samara E., M. Bialer, R. Mechoulam. Pharmacokinetics of cannabidiol in dogs. Drug metabolism and disposition. 1988; 16 (3): 469-472. Retrieved August 12, 2021. https://dmd.aspetjournals.org/content/16/3/469.short

4- Vaughn D, Kulpa J, Paulionis L. Preliminary study of the safety of escalating cannabinoid doses in healthy dogs. Limits in Veterinary Science. 2020; 7. doi: 10.3389 / fvets.2020.00051, accessed August 12, 2021. https://www.frontiersin.org/articles/10.3389/fvets.2020.00051/full

picture: https://www.pexels.com/photo/man-person-love-people-6235648/ by Tima Miroshnichenko from Pexels.com

Hemp and cannabis strains have striking similarities. However, they differ in the amount of THC that is in each one.

THC has psychoactive or mind altering abilities. As a result, it is classified in Appendix 1 and is considered illegal under federal law. Since hemp only contains traces of THC, it does not fall into this category. If anything, it was fully legalized at the federal level with the passage of the Agricultural Act 2018.

The percentage of THC in hemp is his make or break; cross the 0.3% threshold and officially you are dealing with marijuana. Depending on your state laws, you could run into big problems!

When you get the exact amount of THC in a sample, the rubber hits the road. Most laboratories are not equipped with the proper techniques to do this effectively. This difference in quantification and testing methods makes it difficult to standardize in the industry. This is an area that needs to be investigated.

The National Institute of Standards and Technology (NIST) just released the results of a study designed to help laboratories get accurate THC measurements in samples for informed decision-making. This goes hand in hand with their quality assurance program under the CannaQAP brand. The results that have been anonymized were published on the NIST website in July. The reason for maintaining anonymity was to encourage laboratories to participate without worrying about “failing” or “passing” the test.

Hemp samples were prepared with exact amounts of THC, CBD, and other compounds and sent to various laboratories for testing. One hundred and sixteen laboratories participated, including commercial laboratories performing cannabis testing and academic chemical testing laboratories. Almost 83 percent of the participating laboratories sent data to the NIST. The labs measured various cannabinoids (and pollutants) and sent the results to the NIST lab for comparison.

Although the results fluctuated significantly, the researchers said this was normal and to be expected:

“The entire industry does quite well with the target values.”

With this study, NIST hopes to create a learning opportunity for cannabis testing laboratories and help standardize testing methods in the industry. NIST will also use the results to determine the methods and practices that will work best.

Finally, NIST hopes to create a reference material for hemp that will serve as an industry guide.

Image source

https://cbdhealthandwellness.net/2021/08/02/does-cbd-athletic-tape-work/

Cannabidiol (CBD) topicals are nothing new, but with summer in full swing they are becoming very popular as part of a comprehensive skin care regimen, especially when it comes to protecting the skin from the potentially harmful UV rays. It can be dangerous to leave your skin unprotected when you are in the sun for a long time, especially for people with particularly sensitive skin.

CBD has been linked to a seemingly endless list of benefits, and skin protection is just one of them.

The anti-inflammatory properties of CBD for better skin health

For starters, CBD has anti-inflammatory properties that can help keep skin from becoming inflamed from the sun’s rays. [1] And when combined with other active ingredients common in sunscreen products, like zinc oxide, CBD can work wonders to keep skin healthy, hydrated, and protected from the sun.

In fact, it’s the anti-inflammatory properties of CBD that have linked the cannabinoid to a host of health benefits, including promoting better skin. [2] The interaction of CBD with the endocannabinoid system in the body allows it to act at the cellular level to reduce inflammation that is not only at the core of sunburns after a day outdoors, but also eczema, acne, and other skin conditions that cause flare-ups cause due to an underlying inflammation.

CBD skin care products are also often fortified with essential oils to add another protective layer to the skin while adding an aromatic component to the product.

Even in summer, skin care should focus on moisturizing care. Hence, moisturizers should be applied regularly to avoid dry skin, which tends to accompany a day in the sun. Applying a moisturizer under the sunscreen can keep the skin well hydrated while the sunscreen protects against UV rays.

There are more and more moisturizers out there that are already fortified with CBD. However, if you already have a favorite that you use regularly, adding a few drops of CBD oil can help boost the skin’s moisturizing and moisturizing properties.

Lip protection with CBD

In addition to protecting the skin on the face and body, it is important not to ignore the lips. There are several lip products that have both moisturizing properties and added SPF protection from the sun.

But many more are being launched that are fortified with CBD oil to help nourish the lips and prevent problems like dryness, cracking, and more serious sun-related issues. Again, CBD lip products tend to contain other ingredients to maximize protection and hydration, including beeswax and essential oils.

Enjoy the summer safely with high quality CBD infused skin care products.

Image source: Igor Link from Pixabay

References:

1. Nagarkatti, P., et al., “Cannabinoids as novel anti-inflammatory drugs“Future Med Chem., October 2009, 1 (7): 1333-1349.

2. Baswan, SM, et al. “Cannabidiol (CBD) has therapeutic potential for skin health and skin conditions“, Clin Cosmet Investig Dermatol., 2020, 13: 927-942.